Nuvalent Insider Sold Shares Worth $442,980, According to a Recent SEC Filing

MT NewswiresNov 4 16:50 ET

Express News | Reported Earlier: New Report Highlights Nuvectis Pharma's NXP900 Synergy In NSCLC And Anticipates Upcoming NXP800 Data; Positions Nuvectis Among Precision Oncology Leaders Like Nuvalent ($6.6B) And Summit Therapeutics ($15B)

BenzingaOct 28 11:51 ET

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

BusinesswireOct 28 08:21 ET

UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus

Seeking AlphaOct 24 15:32 ET

Express News | UBS Initiates Coverage On Nuvalent With Neutral Rating, Announces Price Target of $100

BenzingaOct 24 07:55 ET

Nuvalent Initiated With a Neutral at UBS

TipRanksOct 24 05:35 ET · Ratings